WA MTP Sector Spotlight: What’s Next for Biotech?

This is a unique opportunity to hear from Leighton, an esteemed Silicon Valley-based serial entrepreneur and venture investor, and network with the sector.

Delivered in partnership with RSM and Brandon Capital, this event has been scheduled to align with a Brandon BioCatalyst Investment Review Committee meeting – we are pleased to welcome commercialisation professionals from leading MRIs and Health Departments across Australia and New Zealand to the event and invite them to network with the WA sector.

Details:

Tuesday 20 August

RSM Australia

Level 32 Exchange Tower

2 The Esplanade, Perth

About the Speaker:

Leighton Read MD is a Silicon Valley-based serial entrepreneur and venture investor. A medical doctor by training, Leighton’s diverse career includes diverse roles and multiple notable ventures.

Prior to joining Brandon Capital, Leighton was a Founder and served as Managing Director and President of the Pharma Division at Affymax NV (acquired by Glaxo in 1995 for $533 million). He was also the founding investor, Chairman and CEO of Aviron (acquired by MedImmune in 2001 for $1.5 billion) and Avidia (acquired by Amgen in 2006 for $380 million).

Leighton completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at Harvard Medical School and School of Public Health. He is currently Non-Executive Chairman of Global Kinetics, and a director of Allay Therapeutics and Glyscend Therapeutics.